Athena Athena

X
[{"orgOrder":0,"company":"Repairon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1\/2 Trial in Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Repairon

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Repairon's lead therapeutic candidate BioVAT-HF, an engineered heart muscle (EHM), is being evaluated in a Phase 1/2 clinical trial as biological ventricular assist tissue in terminal heart failure.

            Lead Product(s): Engineered Heart Muscle

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: BioVAT-HF

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY